Evidence map›Paper›PMID 24318881›Full record

ArticleThe Journal of biological chemistry2014

Hepatic apolipoprotein M (apoM) overexpression stimulates formation of larger apoM/sphingosine 1-phosphate-enriched plasma high density lipoprotein.

Mingxia Liu, Jeongmin Seo, Jeremy Allegood, Xin Bi, Xuewei Zhu, Elena Boudyguina, Abraham K Gebre, Dorit Avni, Dharika Shah, Mary G Sorci-Thomas and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 79 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The FoxOs are in the ApoM house.The Journal of clinical investigation · 2022
    Article
  17. Sphingosine 1-Phosphate Metabolism and Signaling.Advances in experimental medicine and biology · 2022
    Article
  18. Molecular Mechanisms of Sphingolipid Transport on Plasma Lipoproteins.Advances in experimental medicine and biology · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Mingxia LiuFrom the Departments of Pathology-Lipid Sciences and.
Jeongmin Seo
Jeremy Allegood
Xin Bi
Xuewei Zhu
Elena Boudyguina
Abraham K Gebre
Dorit Avni
Dharika Shah
Mary G Sorci-Thomas
Michael J Thomas
Gregory S Shelness
Sarah Spiegel
John S Parks
Wake Forest University · USVirginia Commonwealth University · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
TISSUE CULTURE COREP01HL049373 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SHELNESS, GREGORY S · 1993 to 2012
$23.8M
Inflammation, Atherosclerosis and ApoA-IR01HL064163 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SORCI-THOMAS, MARY G · 2000 to 2013
$4.1M
The Role of Hepatocyte ABCA1 in Lipid Mobilization and TransportR01HL119962 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI PARKS, JOHN S · 2013 to 2022
$3.9M
SPHINGOSINE AS A MODULATOR OF CELLULAR PROLIFERATIONR01GM043880 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI SPIEGEL, SARAH · 1990 to 2023
$3.8M
Sphingosine Kinases in Cancer Cell SignalingR01CA061774 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SPIEGEL, SARAH · 1994 to 2015
$3.8M
Sphingosine-1 phosphate phosphohydrolaseR37GM043880 · NIGMS · VIRGINIA COMMONWEALTH UNIVERSITY · PI SPIEGEL, SARAH · 2003 to 2012
$3.2M
Biophysics of HDL DysfunctionR01HL112270 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI PRITCHARD, KIRKWOOD ARTHUR, SORCI-THOMAS, MARY G · 2012 to 2015
$2.5M
NCI NIH HHS 5P30CA12197NCI NIH HHS P30 CA012197NCI NIH HHS P30 CA016059NHLBI NIH HHS P01HL49373NHLBI NIH HHS R01 HL064163NHLBI NIH HHS R01 HL112270NHLBI NIH HHS R01 HL119962NHLBI NIH HHS R01HL119962NHLBI NIH HHS R01 HL64163NIGMS NIH HHS R37 GM043880NIGMS NIH HHS R37GM043880
6 · The paper itself

Abstract

Apolipoprotein M (apoM), a lipocalin family member, preferentially associates with plasma HDL and binds plasma sphingosine 1-phosphate (S1P), a signaling molecule active in immune homeostasis and endothelial barrier function. ApoM overexpression in ABCA1-expressing HEK293 cells stimulated larger nascent HDL formation, compared with cells that did not express apoM; however, the in vivo role of apoM in HDL metabolism remains poorly understood. To test whether hepatic apoM overexpression increases plasma HDL size, we generated hepatocyte-specific apoM transgenic (APOM Tg) mice, which had an ∼3-5-fold increase in plasma apoM levels compared with wild-type mice. Although HDL cholesterol concentrations were similar to wild-type mice, APOM Tg mice had larger plasma HDLs enriched in apoM, cholesteryl ester, lecithin:cholesterol acyltransferase, and S1P. Despite the presence of larger plasma HDLs in APOM Tg mice, in vivo macrophage reverse cholesterol transport capacity was similar to that in wild-type mice. APOM Tg mice had an ∼5-fold increase in plasma S1P, which was predominantly associated with larger plasma HDLs. Primary hepatocytes from APOM Tg mice generated larger nascent HDLs and displayed increased sphingolipid synthesis and S1P secretion. Inhibition of ceramide synthases in hepatocytes increased cellular S1P levels but not S1P secretion, suggesting that apoM is rate-limiting in the export of hepatocyte S1P. Our data indicate that hepatocyte-specific apoM overexpression generates larger nascent HDLs and larger plasma HDLs, which preferentially bind apoM and S1P, and stimulates S1P biosynthesis for secretion. The unique apoM/S1P-enriched plasma HDL may serve to deliver S1P to extrahepatic tissues for atheroprotection and may have other as yet unidentified functions.

Indexed as

AnimalsApolipoproteinsApolipoproteins EApolipoproteins MFemaleHepatocytesHumansLipocalinsLipoproteins, HDLLiverLysophospholipidsMacrophagesMaleMiceMice, Inbred C57BLMice, Inbred DBAApolipoproteinsApolipoproteins EApolipoproteins MAPOM protein, humanLipocalinsLipoproteins, HDLLysophospholipidsPhosphatidylcholine-Sterol O-AcyltransferaseSphingosinesphingosine 1-phosphateApolipoproteinsApoMHepatocyteHigh Density Lipoprotein (HDL)LiverSphingolipidSphingosine 1-Phosphate

Identifiers

PMID24318881
PMCPMC3908412
OpenAlexW2072913161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.